Viewpoint 3/14/17On the Health Affairs Blog: Rosenberg-Wohl and Coauthors Report on "Wisdom Study" CED Model
Viewpoint 3/10/17On the Health Affairs Blog: Claire Laporte Explains the "Patent Dance" for Biosimilars, and the Importance of Trade Secrets
Viewpoint 3/07/17On the Health Affairs Blog: Bach, Helms and Yu Examine Links Between R&D Costs and Drug Prices
Viewpoint 3/02/17On the Health Affairs Blog: Dubois and Westrich Examine Value Frameworks and Suggest Key Considerations for Improvement
Viewpoint 2/27/17On the Health Affairs Blog: Darrow, Kesselheim and Lasky-Su Analyze the Promise, Challenges and Limitations of the Precision Medicine Initiative and Cancer Moonshot
Viewpoint 2/17/17On the Health Affairs Blog: Galvin and Brennan Suggest Employers Can Take Larger Role in Controlling Drug Costs
Viewpoint 2/14/17On the Health Affairs Blog: Mazer and Curfman Focus On 21st Century Cures Act and Lowered Confidence in FDA Approved Drugs and Devices
Develop state-of-the-art methods for measuring the value of new medical technologies. Educate and advise practitioners, healthcare system stakeholders, and policy makers about these methods to ensure they become a part of standard practice.LEARN MORE
Develop, test, and evaluate new strategies for linking prices to value. Ensure that prices reflect value to both patients and the broader healthcare system, and that patients receive effective care.LEARN MORE
Provide scientifically credible, objective, and timely review of emerging technologies using advanced methods, representing multiple perspectives, to identify key areas of uncertainty and opportunities for value-based pricing.LEARN MORE
Conduct and disseminate research to educate the public and policy makers about the value of medical innovation, and policy reforms that can better ensure value-based pricing in US healthcare markets.LEARN MORE
This viewpoint, authored by Dr. Chandra, Dr. Shafrin, and Dr. Dhawan, describes the differences between various cancer value frameworks and provides recommendations for improving them for clinicians, patients, and payers. In recent years, novel cancer therapies have improved the expected survival of patients but have also increased treatment costs.READ MORE
Health Affairs Blog 2016
While the rest of the health care system is moving toward paying for value, payments for drugs largely continue to be stuck in a 20th century construct that focuses on price, regardless of the health outcomes of each patient. This lack of payment innovation is particularly damaging in an era where on the horizon new treatments and cures promise great benefit for consumers, but also bring great upfront costs for individuals, employers, and governments at every level. This article proposes a new path forward.READ MORE
Harvard Business Review 2015
The meaning of "value" varies by each stakeholder and is thereore the least well understood. Drs. Chandra and Goldman discuss that the right way to think about value in health care delivery is a stream of benefits accrued over a lifetime that is attractive relative to the price paid to acquire them. Using examples with schizophrenia, hepatitis c, and kidney cancer, a value-based design would avoid a "one-size-fits-all" view of drug coverage. Regardless, the challenge is to figure out how to create and develop policies to reward long-term benefits.READ MORE
Research Synthesis Methods 2012
Multi-arm trials are particularly valuable forms of evidence for network meta-analysis (NMA). Trial results are available either as arm-level summaries, where effect measures are reported for each arm or as contrast-level summaries, where the differences in effect between arms compare with the control arm chosen for the trial.READ MORE
Chair of the Panel of Health AdvisorsVIEW BIO
Dr. Nussbaum is currently a Senior Fellow at the Schaeffer Center for Health Policy and Economics at the University of Southern California. Prior to that, Dr. Nussbaum was the executive vice president and chief medical officer of Anthem. During a 15-year tenure, he oversaw medical and pharmacy policy, health improvement, care management, provider contracting, innovative payment models, and outcomes research and drug safety through HealthCore, an Anthem subsidiary. Dr. Nussbaum had a 20-year career as a professor at Harvard Medical School and led a basic and clinical research program at Massachusetts General Hospital where he directed the endocrine group practice. Dr. Nussbaum serves on the boards of the National Quality Forum, the OASIS Institute, and BioCrossroads and previously served as President of the Disease Management Association of America, Chairman of the National Committee for Quality Health Care, Chair of America’s Health Insurance Plan’s Chief Medical Officer Leadership Council, and on the Secretary of Health and Human Services Advisory Committee on Genetics, Health, and Society. Dr. Nussbaum has twice been recognized by Modern Healthcare as one of the “50 Most Influential Physician Executives in Healthcare.”
Executive DirectorVIEW BIO
Dr. Lakdawalla is the Chief Scientific Officer at Precision Health Economics and the Quintiles Chair in Pharmaceutical and Regulatory Innovation at the University of Southern California School of Pharmacy and Price School of Public Policy. He is the winner of numerous awards in health economics, including the Garfield Prize and the Milken Institute Distinguished Research Award. Dr. Lakdawalla is also a Research Associate at the National Bureau of Economic Research, Visiting Scholar at the American Enterprise Institute, and Associate Editor at the Review of Economics and Statistics and the American Journal of Health Economics, and an Editorial Board member at the Journal of Health Economics.
Director of ResearchVIEW BIO
Dr. Shafrin is a Senior Research Economist and the Director of Healthcare Quality and Value-Based Research Methods at Precision Health Economics. He is an expert in value-based purchasing, Medicare reimbursement systems, and advanced econometric analyses using claims data. Dr. Shafrin has extensive experience in estimating the value of new technologies—including traditional and digital medicines—across a variety of disease areas. For instance, Dr. Shafrin has conducted several analyses comparing patient and provider valuations of innovative treatments. He is an expert in the evolving field of value frameworks.
Director of DevelopmentVIEW BIO
Ms. Hillegass is Vice President, Business Development for Precision Health Economics, working closely with clients and key stakeholders on each research engagement. She harnesses over 25 years of global sales and marketing experience and strong knowledge across therapeutic areas, policy and public health issues. Ms. Hillegass has held senior level positions within medical imaging, pharmaceutical and life sciences organizations. She was instrumental in growing the Optum Life Sciences businesses, launching new medicines for Sanofi, and introducing FujiFilm’s digital imaging systems to the U.S. hospital market.
Director of Scientific CommunicationsVIEW BIO
Mr. Linthicum is a Senior Research Scientist and Director of Scientific Communications at Precision Health Economics. At PHE, Mr. Linthicum leads the coordination of multiple research portfolios and specializes in translating scientific content for multiple audiences. Mr. Linthicum has over 10 years of experience in health policy and public health, with experience in policy-facing research in diverse therapeutic areas, including oncology, hepatology, infectious disease, and nutrition.